中國北京與美國新罕布什爾州漢諾威 — 12月24日— 一家臨床階段的獸用腫瘤治療公司Jenga Biosciences, Inc. （Jenga Biosciences）今日宣布其已與專注于動(dòng)物保健醫(yī)藥的生物技術(shù)公司——北京偉杰信生物科技有限公司（偉杰信生物）簽署了一項(xiàng)獨(dú)家許可協(xié)議。根據(jù)協(xié)議，Jenga Biosciences將獲得一款免疫檢查點(diǎn)抑制劑，即犬特異性抗PD-1單克隆抗體的開發(fā)和商業(yè)化權(quán)益。
根據(jù)協(xié)議條款，Jenga Biosciences將獲得該療法在中國以外所有國家的獨(dú)家開發(fā)、生產(chǎn)和商業(yè)化權(quán)利。該協(xié)議約定，未來根據(jù)達(dá)成開發(fā)、注冊和商業(yè)里程碑的情況，Jenga Biosciences潛在將向偉杰信生物支付總額高達(dá)1億美元的款項(xiàng)。
在患犬中開展的探索性臨床研究取得積極結(jié)果
此次授權(quán)的抗PD-1候選藥物已完成一項(xiàng)涵蓋24只患犬的探索性臨床研究。結(jié)果表明，該候選藥物在多種腫瘤類型中均表現(xiàn)出良好的安全性和積極的療效，其中包括在頭頸部腫瘤中展現(xiàn)早期信號(hào)。作為一款完全犬源化的單克隆抗體，該療法專為犬類免疫系統(tǒng)設(shè)計(jì)，為獸醫(yī)腫瘤學(xué)提供了一款“best-in-class”的免疫治療方案。
打造領(lǐng)先的犬類免疫療法組合
此項(xiàng)協(xié)議標(biāo)志著Jenga Biosciences的產(chǎn)品管線迎來了第二個(gè)候選產(chǎn)品，其顯著拓展了該公司的腫瘤學(xué)項(xiàng)目。此次授權(quán)的抗PD-1候選藥物（即JEN-102）有望解鎖聯(lián)合治療策略，并與該公司核心的IL-12免疫療法項(xiàng)目JEN-101形成互補(bǔ)。JEN-101主要針對口腔黑色素瘤及其他實(shí)體瘤。
盡管現(xiàn)有手術(shù)、放療和化療等治療手段可能有效，但仍存在局限性。免疫療法提供了一種差異化的作用機(jī)制，有望實(shí)現(xiàn)更持久的應(yīng)答，從而滿足獸醫(yī)癌癥護(hù)理領(lǐng)域一項(xiàng)重大未被滿足的需求。
對犬類癌癥治療的影響
癌癥仍然是犬類的主要致死原因，每四只犬中有一只在一生中會(huì)確診癌癥。
“抗PD-1療法已經(jīng)徹底改變了人類腫瘤學(xué)的治療格局，從根本上重塑了多種癌癥患者的生存期和生活質(zhì)量，” Jenga Biosciences科學(xué)顧問委員會(huì)負(fù)責(zé)人、獸醫(yī)學(xué)博士、美國獸醫(yī)內(nèi)科學(xué)院（腫瘤學(xué)）認(rèn)證專家Heather Wilson-Robles博士表示。其還表示，“將這類強(qiáng)大的免疫療法帶給犬類患者，是獸醫(yī)腫瘤學(xué)領(lǐng)域一次意義重大的進(jìn)步。”
“我們的目標(biāo)是將世界一流的科學(xué)成果帶給獸醫(yī)，并為癌癥患犬拓展治療選擇，” Jenga Biosciences執(zhí)行董事長兼首席執(zhí)行官Julia Stephanus表示。她還表示，“此次合作通過推進(jìn)一款經(jīng)過臨床驗(yàn)證的用于患犬的抗PD-1療法，使我們離這一目標(biāo)更近了一步。”
“偉杰信生物致力于利用尖端前沿技術(shù)，推動(dòng)高質(zhì)量、創(chuàng)新性的生物免疫療法進(jìn)步，” 偉杰信生物創(chuàng)始人兼董事長羅昊澍博士表示。羅昊澍博士還表示，“我們與Jenga Biosciences優(yōu)勢互補(bǔ)、合作共贏——Jenga在獸醫(yī)腫瘤學(xué)領(lǐng)域的領(lǐng)先優(yōu)勢和偉杰信生物在生物制藥創(chuàng)新方面的綜合專長聯(lián)合互補(bǔ)。我們很高興看到這款抗PD-1療法朝著全球可及的目標(biāo)邁進(jìn)，為癌癥患犬帶來更長、更健康生活的新希望。”
關(guān)于Jenga Biosciences
Jenga Biosciences是一家臨床階段的獸用生物治療公司，致力于開發(fā)用于犬類癌癥的新一代免疫療法。公司專注于將經(jīng)過驗(yàn)證的人類腫瘤學(xué)作用機(jī)制轉(zhuǎn)化為安全、有效且可及的寵物療法，正在打造一個(gè)領(lǐng)先的免疫療法組合，以解決獸醫(yī)學(xué)領(lǐng)域中最嚴(yán)峻且未被滿足的需求。請?jiān)L問www.jengabio.com了解更多信息。
關(guān)于偉杰信生物(VJTBio)
偉杰信生物是一家總部位于中國北京的動(dòng)物保健公司，致力于創(chuàng)新動(dòng)保藥的發(fā)現(xiàn)、開發(fā)、生產(chǎn)和商業(yè)化。公司專注于用于經(jīng)濟(jì)類動(dòng)物繁殖、疫病防控及伴侶動(dòng)物慢性病治療的重組蛋白和抗體的研發(fā)與生產(chǎn)。請?jiān)L問https://global.vjtbio.com了解更多信息。
Jenga Biosciences Licenses Canine Anti-PD-1 Immunotherapy from VJTBio to Advance Next-Generation Cancer Treatments for Dogs
Under the terms of the agreement, Jenga Biosciences receives exclusive rights to develop, manufacture, and commercialize the therapy in all countries outside of China. The agreement provides for potential future payments to VJTBio of up to $100 million, contingent upon the achievement of development, regulatory, and commercial milestones.
Promising Pilot Study Results in Dogs
The licensed anti-PD-1 candidate has completed a pilot clinical study in twenty-four dogs, demonstrating good safety and promising efficacy across multiple tumor types, including early signals in head and neck cancers. As a fully caninized monoclonal antibody, the therapy is designed specifically for the canine immune system, providing a best-in-class immunotherapy approach for veterinary oncology.
Building a Leading Portfolio of Canine Immunotherapies
This agreement marks the second product candidate in Jenga’s pipeline and a notable expansion of its oncology program. JEN-102, the anti-PD-1 candidate, is expected to unlock combination strategies and complement JEN-101, the company’s anchored IL-12 immunotherapy program targeting oral melanoma and other solid tumors.
While current treatments such as surgery, radiation, and chemotherapy can be effective, they are not without limitations. Immunotherapy offers a differentiated mechanism of action with the potential for more durable responses, addressing a critical unmet need in veterinary cancer care.
Impact on Treating Canine Cancer
Cancer remains the leading cause of death in dogs, and 1 in 4 dogs will be diagnosed with cancer in their lifetime.
“Anti-PD-1 therapies have transformed what is possible in human oncology, fundamentally reshaping survival and quality of life across a wide range of cancers,” said Dr. Heather Wilson-Robles, DVM, DACVIM (Oncology), leader of the Scientific Advisory Board for Jenga Biosciences. “Bringing this powerful class of immunotherapies to canine patients represents a meaningful advance for veterinary oncology.”
“Our goal is to bring world-class science to veterinarians and expand the treatment options for dogs with cancer,” said Julia Stephanus, Executive Chair and CEO of Jenga Biosciences. “This collaboration moves us closer to that goal by advancing a clinically validated anti-PD-1 therapy for canine patients.”
“At VJTBio, we are committed to advancing high-quality, innovative biologic immunotherapies powered by cutting-edge technologies,” said Dr. Haoshu Luo, Founder and Chair of VJTBio. “Our collaboration with Jenga Biosciences brings together complementary strengths—Jenga’s leadership in veterinary oncology and our integrated expertise in biologics innovation. We are excited to see this anti-PD-1 therapy progress toward worldwide availability, giving dogs with cancer new hope for longer, healthier lives.”
About Jenga Biosciences
Jenga Biosciences is a clinical-stage veterinary biotherapeutics company developing next-generation immunotherapies for canine cancer. With a focus on translating proven human oncology mechanisms into safe, effective, and accessible treatments for pets, Jenga is building a leading portfolio of immunotherapies to address the most serious unmet needs in veterinary medicine. Learn more at www.jengabio.com.
About VJTBio
VJTBio is an animal healthcare company based in Beijing, China, dedicated to the discovery, development, production, and commercialization of innovative veterinary medicines. The company specializes in recombinant proteins and antibodies for veterinary use in livestock reproduction, infectious diseases, and chronic diseases in companion animals. Learn more at https://global.vjtbio.com.
關(guān)注偉杰信公眾號(hào)